Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom. Show more
Location: 14/15 Conduit Street, London, W1S 2XJ, United Kingdom | Website: https://www.tizianalifesciences.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
183.5M
52 Wk Range
$0.63 - $1.91
Previous Close
$1.57
Open
$1.56
Volume
171,111
Day Range
$1.51 - $1.56
Enterprise Value
172.5M
Cash
3.724M
Avg Qtr Burn
-381.5K
Insider Ownership
43.06%
Institutional Own.
2.73%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Foralumab Details COVID-19 | Phase 2 Initiation | |
Milciclib (pan-CDK inhibitor) Details Hepatocellular carcinoma, Solid tumor/s | Phase 2 Initiation | |
Intranasal Foralumab (anti-CD3 mAb) Details Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) | Phase 2a Update | |
Foralumab (anti-CD3 mAb) Details Crohns disease | Phase 1b Data readout | |
Intranasal Foralumab Details Neurodegenerative disease, Alzheimer's disease | Phase 1 Data readout | |
Intranasal Foralumab (anti-CD3 mAb) Details Neurodegenerative disease, Amyotrophic lateral sclerosis | IND Acceptance decision |